BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29125112)

  • 1. Clinical Values of Combined Diffused Optical Tomography and PET-CT in the Diagnosis of Breast Cancer.
    Wang HY; Jin XN; Jiang YX; Zhu ZH; Xu Y; Zhu QL; Dai Q; Li JC; Li F; Sun Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Oct; 39(5):682-687. PubMed ID: 29125112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Value of Positron Emission Tomography-Computed Tomography Combined with Ultrasound in Detection of Primary Tumors in Patients with Malignant Ascites.
    Liu J; Liu G; Liu X; Zhu X; Wang Y; Gou B; You L
    Cancer Biother Radiopharm; 2019 Apr; 34(3):203-207. PubMed ID: 30585766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
    J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET/CT in the diagnosis of recurrent breast cancer.
    Murakami R; Kumita S; Yoshida T; Ishihara K; Kiriyama T; Hakozaki K; Yanagihara K; Iida S; Tsuchiya S
    Acta Radiol; 2012 Feb; 53(1):12-6. PubMed ID: 22067206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of [18F]fluorodeoxyglucose positron emission tomography-computed tomography, sonography, and sonographically guided fine-needle aspiration biopsy in the diagnosis of axillary lymph nodes in patients with breast cancer: comparison of diagnostic performance.
    Sohn YM; Hong IK; Han K
    J Ultrasound Med; 2014 Jun; 33(6):1013-21. PubMed ID: 24866608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography for the detection of proximal synchronous lesions in patients with obstructive colorectal cancer.
    Kim WS; Lee HS; Lee JM; Kwak MS; Hwang SW; Park SH; Yang DH; Kim KJ; Myung SJ; Yang SK; Byeon JS
    J Gastroenterol Hepatol; 2017 Feb; 32(2):401-408. PubMed ID: 27418280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
    Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
    Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.
    Taghipour M; Sheikhbahaei S; Trahan TJ; Subramaniam RM
    Nucl Med Commun; 2016 Jun; 37(6):602-8. PubMed ID: 27110955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
    Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
    Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
    Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
    Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
    Xiao Y; Wang L; Jiang X; She W; He L; Hu G
    Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.